XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Incentive Plans (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Options, RSUs Activity under 2014 Equity Incentive Plan and 2016 Inducement Plan and Related Information The following table summarizes option and RSU activity under the Company’s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan, and 2019 Inducement Equity Incentive Plan, and related information:
Shares
Available
for Grant		Stock
Options
Outstanding		Weighted-
Average
Exercise
Price		Number of
RSU Shares		Weighted-
Average
Grant Date
Fair Value
Balance—December 31, 20221,490,462 2,921,925 $28.13 3,094,396 $37.39 
Additional shares authorized2,141,330 — — — — 
Common stock awards for services(7,649)— — — — 
RSUs granted(1,262,588)— — 1,262,588 15.27 
RSUs vested— — — (170,077)52.76 
Options granted(418,564)418,564 15.50 — — 
Options exercised— (820)2.06 — — 
Repurchase of common stock under employee incentive plans50,254 — — — — 
RSUs forfeited91,291 — — (91,291)36.78 
Options forfeited12,949 (12,949)31.32 — — 
Options expired78,024 (78,024)33.81 — — 
Balance—March 31, 20232,175,509 3,248,696 $26.52 4,095,616 $29.87 
Summary of Options Outstanding and Exercisable Vested or Expected to Vest Options outstanding that have vested and are expected to vest at March 31, 2023 are as follows:
Number of Shares Issued
(In thousands)		Weighted-Average
Exercise Price		Weighted-Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
(In thousands)
Vested1,273 $25.39 5.72$1,558 
Expected to vest1,695 27.05 8.973 
Total2,968 $1,561 
Summary of Weighted-Average Assumptions Used to Estimate Fair Values of Share-Based Awards The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:
Three Months Ended March 31,
20232022
Employee stock options
Expected term (in years)6.06.0
Expected volatility78.63%76.93%
Risk-free interest rate3.46%1.65%
Expected dividend yield—%—%
Employee stock purchase plan
Expected term (in years)0.50.5
Expected volatility77.88%67.79%
Risk-free interest rate4.94%1.06%
Expected dividend yield—%—%
Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs
The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March 31, 2023 and 2022, included in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of testing services$479 $19 
Cost of product360 128 
Cost of patient and digital solutions402 192 
Research and development1,962 2,190 
Sales and marketing3,737 3,123 
General and administrative6,814 4,982 
Total$13,754 $10,634